PURPOSE: Overweight or obese breast cancer patients have a worse prognosis compared with normal-weight patients. This may be attributed to hyperinsulinemia and dysregulation of adipokine levels associated with overweight and obesity. Here, we evaluate whether low levels of adiponectin and a greater level of insulin resistance are associated with breast cancer mortality and all-cause mortality. PATIENTS AND METHODS: We measured glucose, insulin, and adiponectin levels in fasting serum samples from 527 women enrolled in the Health, Eating, Activity, and Lifestyle (HEAL) Study, a multiethnic, prospective cohort study of women diagnosed with stage I-IIIA breast cancer. We evaluated the association between adiponectin and insulin and glucose levels (expressed as the Homeostatic Model Assessment [HOMA] score) represented as continuous measures and median split categories, along with breast cancer mortality and all-cause mortality, using Cox proportional hazards models. RESULTS: Increasing HOMA scores were associated with reduced breast cancer survival (hazard ratio [HR], 1.12; 95% CI, 1.05 to 1.20) and reduced all-cause survival (HR, 1.09; 95% CI, 1.02 to 1.15) after adjustment for possible confounders. Higher levels of adiponectin (above the median: 15.5 μg/mL) were associated with longer breast cancer survival (HR, 0.39; 95% CI, 0.15 to 0.95) after adjustment for covariates. A continuous measure of adiponectin was not associated with either breast cancer-specific or all-cause mortality. CONCLUSION: Elevated HOMA scores and low levels of adiponectin, both associated with obesity, were associated with increased breast cancer mortality. To the best of our knowledge, this is the first demonstration of the association between low levels of adiponectin and increased breast cancer mortality in breast cancer survivors.
PURPOSE: Overweight or obese breast cancerpatients have a worse prognosis compared with normal-weight patients. This may be attributed to hyperinsulinemia and dysregulation of adipokine levels associated with overweight and obesity. Here, we evaluate whether low levels of adiponectin and a greater level of insulin resistance are associated with breast cancer mortality and all-cause mortality. PATIENTS AND METHODS: We measured glucose, insulin, and adiponectin levels in fasting serum samples from 527 women enrolled in the Health, Eating, Activity, and Lifestyle (HEAL) Study, a multiethnic, prospective cohort study of women diagnosed with stage I-IIIA breast cancer. We evaluated the association between adiponectin and insulin and glucose levels (expressed as the Homeostatic Model Assessment [HOMA] score) represented as continuous measures and median split categories, along with breast cancer mortality and all-cause mortality, using Cox proportional hazards models. RESULTS: Increasing HOMA scores were associated with reduced breast cancer survival (hazard ratio [HR], 1.12; 95% CI, 1.05 to 1.20) and reduced all-cause survival (HR, 1.09; 95% CI, 1.02 to 1.15) after adjustment for possible confounders. Higher levels of adiponectin (above the median: 15.5 μg/mL) were associated with longer breast cancer survival (HR, 0.39; 95% CI, 0.15 to 0.95) after adjustment for covariates. A continuous measure of adiponectin was not associated with either breast cancer-specific or all-cause mortality. CONCLUSION: Elevated HOMA scores and low levels of adiponectin, both associated with obesity, were associated with increased breast cancer mortality. To the best of our knowledge, this is the first demonstration of the association between low levels of adiponectin and increased breast cancer mortality in breast cancer survivors.
Authors: Y Arita; S Kihara; N Ouchi; M Takahashi; K Maeda; J Miyagawa; K Hotta; I Shimomura; T Nakamura; K Miyaoka; H Kuriyama; M Nishida; S Yamashita; K Okubo; K Matsubara; M Muraguchi; Y Ohmoto; T Funahashi; Y Matsuzawa Journal: Biochem Biophys Res Commun Date: 1999-04-02 Impact factor: 3.575
Authors: Yu Wang; Janice B Lam; Karen S L Lam; Jing Liu; Michael C Lam; Ruby L C Hoo; Donghai Wu; Garth J S Cooper; Aimin Xu Journal: Cancer Res Date: 2006-12-01 Impact factor: 12.701
Authors: Esther K Wei; Edward Giovannucci; Charles S Fuchs; Walter C Willett; Christos S Mantzoros Journal: J Natl Cancer Inst Date: 2005-11-16 Impact factor: 13.506
Authors: Sao Jiralerspong; Shana L Palla; Sharon H Giordano; Funda Meric-Bernstam; Cornelia Liedtke; Chad M Barnett; Limin Hsu; Mien-Chie Hung; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo Journal: J Clin Oncol Date: 2009-06-01 Impact factor: 44.544
Authors: Bette J Caan; Marilyn L Kwan; Georgina Hartzell; Adrienne Castillo; Martha L Slattery; Barbara Sternfeld; Erin Weltzien Journal: Cancer Causes Control Date: 2008-08-28 Impact factor: 2.506
Authors: Anne K Swisher; Jame Abraham; Daniel Bonner; Diana Gilleland; Gerald Hobbs; Sobha Kurian; Mary Anne Yanosik; Linda Vona-Davis Journal: Support Care Cancer Date: 2015-03-01 Impact factor: 3.603
Authors: Christina M Dieli-Conwright; Frank C Sweeney; Kerry S Courneya; Debu Tripathy; Nathalie Sami; Kyuwan Lee; Thomas A Buchanan; Darcy Spicer; Leslie Bernstein; Joanne E Mortimer; Wendy Demark-Wahnefried Journal: Cancer Date: 2018-11-30 Impact factor: 6.860
Authors: Shannon M Conroy; Gertraud Maskarinec; Lynne R Wilkens; Kami K White; Brian E Henderson; Laurence N Kolonel Journal: Breast Cancer Res Treat Date: 2011-04-16 Impact factor: 4.872
Authors: Stephen D Hursting; John Digiovanni; Andrew J Dannenberg; Maria Azrad; Derek Leroith; Wendy Demark-Wahnefried; Madhuri Kakarala; Angela Brodie; Nathan A Berger Journal: Cancer Prev Res (Phila) Date: 2012-10-03
Authors: Avonne E Connor; Richard N Baumgartner; Christina Pinkston; Kathy B Baumgartner Journal: J Womens Health (Larchmt) Date: 2013-03-26 Impact factor: 2.681
Authors: Catherine Duggan; Ching-Yun Wang; Marian L Neuhouser; Liren Xiao; Ashley Wilder Smith; Kerryn W Reding; Richard N Baumgartner; Kathy B Baumgartner; Leslie Bernstein; Rachel Ballard-Barbash; Anne McTiernan Journal: Int J Cancer Date: 2012-09-01 Impact factor: 7.396